Federated Hermes Inc. Reduces Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. lowered its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 28.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 585,115 shares of the company's stock after selling 238,372 shares during the period. Federated Hermes Inc. owned about 1.23% of Amphastar Pharmaceuticals worth $16,962,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in AMPH. Signaturefd LLC grew its position in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock worth $25,000 after purchasing an additional 520 shares during the last quarter. IFP Advisors Inc purchased a new stake in shares of Amphastar Pharmaceuticals in the first quarter valued at about $34,000. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $38,000. GAMMA Investing LLC boosted its stake in shares of Amphastar Pharmaceuticals by 46.6% during the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Wells Fargo & Company reduced their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $32.33.

Amphastar Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ:AMPH opened at $21.21 on Friday. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The company has a quick ratio of 2.02, a current ratio of 2.95 and a debt-to-equity ratio of 0.80. The firm's 50-day simple moving average is $23.71 and its 200-day simple moving average is $26.76. The company has a market cap of $999.84 million, a price-to-earnings ratio of 7.68 and a beta of 0.76.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.